C-Met receptor regulation by angiotensin IV (AT
View Patent ↗The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis, cancer metastasis, adipogenesis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, including cancer, obesity and conditions associated with obesity, and other disorders, for example, by altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor.
1. A method for treating obesity or solid tumors associated with obesity, comprising administering to a subject in need thereof a composition that comprises an isolated angiotensin-like factor that is a hepatocyte growth factor (HGF) hinge region mimic, under conditions and for a time sufficient for the angiotensin-like factor to interact with one or both of i) a cell surface c-Met receptor on a preadipocyte or adipocyte and ii) a native HGF hinge region polypeptide in the subject, wherein the angiotensin-like factor is capable of specifically binding to one or both of the cell surface c-Met receptor and the native HGF hinge region polypeptide, thereby treating obesity or the solid tumors associated with obesity, wherein said angiotensin-like factor is
a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn-Cys [SEQ ID NO:82]; or
a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7 or 6 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn (SEQ ID NO: 93).
2. The method according to claim 1 , wherein the solid tumor is of a type selected from breast, endometrial, colorectal, kidney, prostate, gallbladder, pancreatic and esophageal, thyroid, lung, cervical, ovarian, liver thyroid cancer, and melanoma.
3. A method for altering a hepatocyte growth factor activity or a c-Met receptor activity in one cell or in a plurality of cells, comprising: contacting a cell or plurality of cells with a composition that comprises an isolated angiotensin-like factor that is a hepatocyte growth factor (HGF) hinge region mimic, under conditions and for a time sufficient for the angiotensin-like factor to interact with one or both of i) a cell surface c-Met receptor and ii) a native HGF hinge region polypeptide, the native HGF hinge region polypeptide comprising the amino acid sequence Lys-Asp-Tyr-Ile-Arg-Asn-Cys [SEQ ID NO:82], wherein the angiotensin-like factor inhibits one or both of binding of a native HGF hinge region polypeptide to the cell surface c-Met receptor and dimerization of native HGF monomers, thereby altering HGF activity or c-Met receptor activity, and wherein said isolated angiotensin-like factor is
a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn-Cys [SEQ ID NO:82]; or
a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7 or 6 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn (SEQ ID NO: 93);
and wherein the step of contacting is conducted in vivo or ex vivo.
4. The method of claim 3 wherein the hepatocyte growth factor activity or the c-Met receptor activity comprises at least one activity that is selected from the group consisting of (i) induction of cellular proliferation, (ii) induction of cell scattering or migration, and (iii) alteration of a c-Met receptor pathway component phosphorylation state.
5. The method of claim 4 wherein alteration of a c-Met receptor pathway component phosphorylation state comprises induction of Gab 1 activation.
6. The method of claim 3 wherein the cell or plurality of cells comprises a tissue or an organ.
7. The method of claim 3 wherein the hepatocyte growth factor activity or c-Met receptor activity in the cell is decreased subsequent to the step of contacting, relative to the hepatocyte growth factor activity or c-Met receptor activity in the cell prior to the step of contacting.
8. The method of claim 7 wherein the hepatocyte growth factor activity or c-Met receptor activity comprises an activity that is selected from the group consisting of (i) induction of cell proliferation, (ii) induction of cell migration, (iii) induction of extracellular matrix disruption, (iv) induction of dysregulation of apoptosis, (v) induction of cellular extravasation, (vi) induction of altered expression of an adhesion molecule that is selected from the group consisting of CD44, catenin, catenin β, catenin δ1, MMP-1, PAI-1, thrombospondin 1, and integrin α-2, and (vii) induction of altered expression of an angiogenesis-related molecule that is selected from the group consisting of: Adamts 1, CD36, Connective tissue growth factor, Pecam 1, Cxcl 4, restin, Ccl 2, TNF-α, VEGF-α, and VEGF-β.
9. The method of claim 1 , wherein the angiotensin-like factor is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, or 6 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn [SEQ ID NO:93].
10. A method for treating solid tumors associated with obesity, comprising administering to a subject in need thereof a composition that comprises an isolated angiotensin-like factor that is a hepatocyte growth factor (HGF) hinge region mimic, under conditions and for a time sufficient for the angiotensin-like factor to interact with one or both of i) a cell surface c-Met receptor on a preadipocyte or adipocyte and ii) a native HGF hinge region polypeptide in the subject, wherein the angiotensin-like factor is capable of specifically binding to one or both of the cell surface c-Met receptor and the native HGF hinge region polypeptide, thereby treating solid tumors associated with obesity, wherein the angiotensin-like factor is
a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn-Cys [SEQ ID NO:82]; or
a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7 or 6 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn (SEQ ID NO: 93).
11. The method of claim 10 , wherein the angiotensin-like factor is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, or 6 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn [SEQ ID NO:93].
12. A method for reducing fat in a subject, comprising administering to a subject in need thereof a composition that comprises an isolated angiotensin-like factor that is a hepatocyte growth factor (HGF) hinge region mimic, under conditions and for a time sufficient for the angiotensin-like factor to interact with one or both of i) a cell surface c-Met receptor on a preadipocyte or adipocyte and ii) a native HGF hinge region polypeptide in the subject, wherein the angiotensin-like factor is capable of specifically binding to one or both of the cell surface c-Met receptor and the native HGF hinge region polypeptide, thereby reducing fat in the subject, the angiotensin-like factor is
a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8 or 7 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn-Cys [SEQ ID NO:82]; or
a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7 or 6 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn (SEQ ID NO: 93).
13. The method of claim 12 , wherein the angiotensin-like factor is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, or 6 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn [SEQ ID NO:93].
14. The method of claim 1 , wherein the angiotensin-like factor is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, or 7 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn-Cys [SEQ ID NO:82].
15. The method of claim 3 , wherein the angiotensin-like factor is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, or 7 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn-Cys [SEQ ID NO:82].
16. The method of claim 10 , wherein the angiotensin-like factor is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, or 7 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn-Cys [SEQ ID NO:82].
17. The method of claim 12 , wherein the angiotensin-like factor is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, or 7 amino acids that comprises Lys-Asp-Tyr-Ile-Arg-Asn-Cys [SEQ ID NO:82].